Off-label use of tesamorelin in adults with visceral obesity and metabolic syndrome exists in clinical practice, and the mechanistic rationale is sound
Patients interested in learning more about BPC-157 therapy can review our BPC-157 Therapy Program and our Peptide Therapy Clinic
Retatrutide also showed dose-dependent reductions in body weight at 36 weeks (3.19% for 0.5 mg group vs
Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy
Artificial Sweeteners and Food Dyes Some studies suggest that certain synthetic food dyes and artificial sweeteners, like aspartame, can place an additional burden on the liver's detoxification pathways
Meaning: In patients with advanced chronic kidney disease, compared with placebo, low-dose rivaroxaban did not reduce cardiovascular events, but increased rates of major bleeding